FIGS, Inc., the direct-to-consumer healthcare apparel company, has experienced a dramatic round-trip over the past year. After trading below $4 in early 2025, the stock staged a powerful recovery, surging above $17 by March 2026 behind strong earnings and a flurry of analyst upgrades. Since that peak, however, shares have retreated sharply, settling near $9.50 as of late July 2026. The question now confronting investors is whether the growth story can regain enough momentum to push the stock toward $20 — a psychologically significant level that would represent new highs for this cycle and align with the most bullish Wall Street targets.
Founded in 2013 by Heather Hasson and Trina Spear, FIGS disrupted the staid medical uniform industry by designing premium scrubs and healthcare apparel with the fit, feel, and branding sensibility of athleisure. The company went public in May 2021 at $22 per share and briefly traded above $50 during the pandemic-era surge in healthcare spending. Today, FIGS generates trailing twelve-month revenue of approximately $666 million, serves over 3 million active customers, and operates across North America, Europe, Asia Pacific, and the Middle East through its e-commerce platform and a growing network of physical retail locations.
Several catalysts could support a move toward $20. First, international expansion is delivering tangible results — international sales grew approximately 50% year-over-year in the most recent quarter. The company's TEAMS platform, which serves healthcare institutions through bulk purchasing, represents a largely untapped B2B opportunity. Management raised full-year 2026 revenue growth guidance to 14%–16% following Q1 results that delivered $159.9 million in revenue, a 28% increase from the prior year. The company's balance sheet remains a source of strength, with $277 million in net cash and no long-term debt, providing ample flexibility for share buybacks and strategic investments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Wall Street has taken notice. Oppenheimer carries a $22 price target with an Outperform rating, while BTIG maintains a Buy rating with a $20 target. KeyBanc's Overweight rating and $19 target reflect confidence that the company's "growth algorithm remains intact," citing healthy customer engagement trends and limited resistance to recent pricing actions.
Tariffs remain the most significant obstacle. Section 122 tariffs, currently at 10% and potentially rising to 15%, directly pressure gross margins on imported goods. Management acknowledged that freight cost headwinds and the pause of a duty drawback program will create an uneven margin cadence throughout 2026. While Q1 gross margin improved modestly to 67.7%, the full-year outlook assumes only slight improvement over 2025's 66.5%.
Competition also deserves attention. The healthcare apparel market, while historically fragmented, is attracting attention from larger players. Lower-priced alternatives continue to test FIGS's premium positioning, and the company must demonstrate that its brand strength can sustain pricing power without relying on promotions that erode profitability.
The stock's technical picture presents a mixed outlook. After peaking at $17.48 in early March 2026, shares have fallen below both the 50-day moving average near $12.69 and the 200-day moving average near $12.79 — a configuration that typically signals bearish momentum. The $9–$10 zone represents an important support area; a breakdown below this range could expose the stock to the mid-$7 area, where Goldman Sachs's prior price target sat before its February upgrade. On the upside, reclaiming the $12–$13 region would be a necessary first step toward rebuilding confidence, with the prior peak near $17 serving as the next major resistance zone before $20 becomes a realistic discussion. From what I see, monitoring these levels closely helps frame the risk-reward picture.
The analyst community holds a Moderate Buy consensus on FIGS, with an average 12-month price target near $15.93, according to MarketBeat data from 11 covering analysts. However, targets span a wide range — from a bearish $7.50 to a bullish $22.00 — reflecting genuine disagreement about the company's trajectory. The clustering of targets between $15 and $20 suggests that even bullish analysts are tempering enthusiasm with caution around margin recovery and valuation. Notably, the average target represents approximately 56% upside from current levels but still falls meaningfully short of $20, underscoring that the $20 objective requires execution beyond the consensus base case.
Even after its recent decline, FIGS trades at a trailing P/E ratio above 40 — a premium multiple that leaves little room for disappointment. The forward P/E near 34 suggests the market expects significant earnings growth to materialize. For the stock to reach $20 without multiple expansion, EPS would need to roughly double from current levels. With FY2026 consensus EPS estimates around $0.25–$0.27 and FY2027 projections near $0.35, reaching $20 would likely require maintaining an elevated growth multiple while delivering consistent earnings beats — a demanding but not impossible combination.
The path to $20 for FIGS stock is plausible but conditional. The company's revenue growth trajectory, international momentum, fortress balance sheet, and growing customer base provide a credible foundation. However, the near-term reality includes tariff headwinds, margin uncertainty, and a stock that has lost technical momentum. Reaching $20 would likely require multiple catalysts to align: successful mitigation of tariff impacts, sustained margin expansion, accelerating international contribution, and a broader market environment supportive of growth-at-a-reasonable-price narratives. Investors should monitor the upcoming Q2 earnings report in early August 2026 for updated guidance on margins, tariff assumptions, and progress on international initiatives — these will be critical signposts on the road to $20.
Navigating a stock with as much volatility as FIGS requires timely, data-driven insight. In my own analysis, I often rely on Tickeron’s AI Daily Buy/Sell Signals to monitor shifting conditions across thousands of stocks and ETFs. The platform’s AI evaluates technical patterns and fundamentals to generate Buy, Sell, or Hold signals, helping me stay ahead of potential trend changes without replacing my own due diligence.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 50-day moving average for FIGS moved below the 200-day moving average on July 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on July 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FIGS as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FIGS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for FIGS entered a downward trend on July 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FIGS's RSI Oscillator exited the oversold zone, of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for FIGS just turned positive on July 16, 2026. Looking at past instances where FIGS's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FIGS advanced for three days, in of 248 cases, the price rose further within the following month. The odds of a continued upward trend are .
FIGS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. FIGS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.689) is normal, around the industry mean (6.249). P/E Ratio (43.227) is within average values for comparable stocks, (30.563). FIGS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.112). FIGS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.023). FIGS's P/S Ratio (2.682) is very high in comparison to the industry average of (0.900).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FIGS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ApparelFootwear